Source: Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Charifa Awada, Yann Grobs, Wen-Hui Wu, Karima Habbout, Charlotte Romanet, Sandra Breuils-Bonnet, Eve Tremblay, Sandra Martineau, Roxane Paulin, Sébastien Bonnet, Steeve Provencher, François Potus, Olivier Boucherat. R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models. Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020

Member's Comments

No comment yet.

Related content which might interest you: A novel murine model of severe pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Two rat models of hemolysis-induced pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Formation of typical vascular lesions in a new experimental model of pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 How does inflammation contribute to pulmonary hypertension? Source: Eur Respir J, 51 (1) 1702403; 10.1183/13993003.02403-2017 Year: 2018 Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Chronic thromboembolic pulmonary hypertension: animal models Source: Eur Respir J 2013; 41: 1200-1206 Year: 2013 Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2015; 46: 431-443 Year: 2015 MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology Source: Eur Respir Rev 2009; 19: 59-63 Year: 2010 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 Zamicastat decreases cardiac arrhythmias in a rat model of pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Bosentan fails to prevent the development of pulmonary arterial hypertension in athymic rats exposed to chronic hypoxia Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Systemic consequences of pulmonary arterial hypertension Source: International Congress 2019 – State of the art session: Pulmonary vascular diseases Year: 2019 Systemic oxygenation affects post-transplantation edema formation and pulmonary artery hypertension in an ex vivo animal model Source: Annual Congress 2012 - Lung transplantation: studies in candidates and recipients Year: 2012